Gene sequencing company Illumina will pay $8 billion in cash and stock to buy cancer screening startup Grail, the companies said.
Illumina buys Jeff Bezos-backed cancer-testing firm Grail in deal worth $8 billion
Posted in biotech/medical
Posted in biotech/medical
Gene sequencing company Illumina will pay $8 billion in cash and stock to buy cancer screening startup Grail, the companies said.